|1.||Scorilas, Andreas: 7 articles (03/2015 - 01/2007)|
|2.||Cavaletti, Guido: 7 articles (04/2012 - 11/2003)|
|3.||Coveñas, Rafael: 6 articles (07/2014 - 06/2011)|
|4.||Muñoz, Miguel: 6 articles (07/2014 - 06/2011)|
|5.||Wang, Yang: 6 articles (01/2013 - 07/2002)|
|6.||Moretti, Massimo: 5 articles (08/2015 - 01/2011)|
|7.||Dominici, Luca: 5 articles (08/2015 - 01/2011)|
|8.||Monarca, Silvano: 5 articles (08/2015 - 01/2011)|
|9.||Villarini, Milena: 5 articles (08/2015 - 01/2011)|
|10.||Chen, Zhe-Sheng: 5 articles (03/2015 - 01/2009)|
01/01/2013 - "Although very much progress has been attained in the development of new therapies, there is a clear need of more efficient and selective antitumor drugs for the effective treatment of many types of cancer. "
01/01/2005 - "The elucidation of CRC biology is paving the way to the development of molecularly targeted strategies, and results from controlled clinical trials have already demonstrated that some agents targeting tumor-specific molecules can significantly improve the therapeutic efficacy of conventional antineoplastic drugs. "
03/01/2015 - "Multidrug resistance (MDR), defined as the resistance of cancer cells to compounds with diverse structures and mechanisms of actions, significantly limits the efficacy of antitumor drugs. "
11/01/2014 - "High CYP3A4 expression sensitizes tumor cells to certain antitumor agents while for others it can lower their therapeutic efficacy. "
07/01/1991 - "Clinical predictability of preclinical test for antitumor agents has not been significantly improved even after the use of a human tumor/nude mouse model. "
|2.||Breast Neoplasms (Breast Cancer)
10/01/1996 - "Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. "
01/01/1989 - "Since it seems most unlikely that a new wonder drug for breast cancer will emerge in the next few years, then it is to our existing armamentarium of antineoplastic agents that we will have to turn for improved therapeutic results. "
02/20/1983 - "[Correlation between antitumor effects against human mammary carcinoma (MX-1) in nude mice and clinical efficacy of human breast cancer in thirty-four antitumor agents]."
04/01/2013 - "These findings indicate that, in addition to cell proliferation and apoptosis, cellular senescence could be used as a potential biomarker of response in breast cancer prevention and therapy studies with rexinoids and possibly with other antitumor agents."
01/01/2012 - "Previous studies show that CD44 down-regulation causes CD44(+)CD24(-) breast cancer stem cells to differentiate into non-stem cells that are sensitive to antitumor drugs and lose many characteristics of the original cells. "
05/01/2009 - "By using such systems, it has been possible to identify the cells in which leukemia originates; to recognize a functional hierarchy within the hematopoietic system of leukemia patients; to identify factors, soluble and cell-associated, that regulate leukemic growth; and to study the effects of different antineoplastic drugs. "
08/30/1988 - "Here we present a study in which the MTT assay has been adapted to assess the effect of antineoplastic drugs on lymphoblasts of children with leukemia."
09/01/1982 - "The study of cell kinetics may provide benefits to know the effect of antitumor drugs during the treatment of human leukemia."
09/01/1965 - "[Leukemia P 1534 as an experimental model for the study of antineoplastic drugs]."
02/01/2009 - "We investigated the effects on cellular proliferation in vitro when combining NaB with antineoplastic drugs commonly used to treat leukemias. "
04/01/1985 - "The stability of the cell-killing efficacy of 10 antitumor drugs stored at different temperatures and concentrations was evaluated on an established human colon carcinoma cell line using the colony formation technique. "
05/01/2011 - "Thus, the purpose of this study was to evaluate and directly compare the cytotoxic efficacy of ascorbate compared to DHA, and to analyse if ascorbate at pharmacological concentrations affects the efficacy of antineoplastic agents in prostate carcinoma cells. "
08/01/2013 - "The present study provides a promising new approach to select antineoplastics and improve drug efficacy in carcinoma cells that form GJs."
12/01/2012 - "Overall the results indicate that D3CLP, in combined preparation with antineoplastic drugs, is a good candidate for pre-clinical studies in the treatment of different carcinoma cell types."
07/01/2010 - "The aim of the present study was to investigate the effects of these two antineoplastic drugs on the apoptotic index and cell cycle kinetics of urinary bladder transitional carcinoma cell lines with wild-type or mutant TP53 (RT4: wild type for TP53; 5637 and T24: mutated TP53). "
|5.||Neoplasm Metastasis (Metastasis)
08/01/2000 - "Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by a computer-assisted image analysis."
05/01/2014 - "The aim of our study was to understand the role of pDCs in pulmonary metastases during the treatment with conventional antitumor agents. "
01/30/2014 - "ROCK1 and ROCK2 mediate important processes such as cell migration, invasion and metastasis, making them good targets for the development of antitumor agents. "
06/01/2012 - "As the eGFP and luc2 combination are superior to single reporter genes in their ability to mark cells in vivo and in vitro, these cells may provide a visualizable, convenient and sensitive platform for research on the mechanisms of metastasis and the development of new antitumor drugs for human TNBC."
10/01/2008 - "For severe bone lesion, multifunctional implants integrating with antitumor drugs/small molecules and bone forming factors could be effective to reconstruct bone defects and to improve the quality of life in patients with bone metastasis."
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)